Особенности клинического течения и лечения наследственных форм рака молочной железы и рака яичников
https://doi.org/10.17650/1994-4098-2020-16-4-54-65
Аннотация
В статье освещены проблемы современного хирургического и системного лечения больных с наследственными (в том числе ассоциированными с мутациями генов BRCA1/2) формами рака молочной железы и яичника. Рассмотрены вопросы, касающиеся особенностей клинического течения первично-множественных опухолей, а также их чувствительности к цитостатической
и таргетной терапии.
Ключевые слова
рак молочной железы,
рак яичника,
первично-множественные опухоли,
BRCA1,
BRCA2,
CHEK2,
PARP-ингибиторы
Об авторах
В. В. Семиглазов
ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России; ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова» Минздрава России
Россия
Россия
Владислав Владимирович Семиглазов
197022 Санкт-Петербург, ул. Льва Толстого, 6–8
197758 Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68
А. Э. Протасова
ФБОУ ВО «Санкт-Петербургский государственный университет»
Россия
199034 Санкт-Петербург, Университетская набережная, 7–9
Россия
199034 Санкт-Петербург, Университетская набережная, 7–9
Г. К. Каликеев
ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России
Россия
197022 Санкт-Петербург, ул. Льва Толстого, 6–8
Россия
197022 Санкт-Петербург, ул. Льва Толстого, 6–8
Список литературы
1. Злокачественные новообразования в России в 2018 году: заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019. 250 с.
2. Valachis A., Nearchou A.D., Lind P. Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis. Breast Cancer Res Treat 2014;144(3):443–55. DOI: 10.1007/s10549-014-2890-1.
3. Берштейн Л.М. Роль экстрагонадных эстрогенов и гормональный канцерогенез. Вестник Российской академии медицинских наук 2007;(8):54.
4. Yager J.D., Davidson N.E. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270–82. DOI: 10.1056/NEJMra050776.
5. Chang E.C., Frasor J., Komm B. et al. Impact of estrogen receptor β on gene networks regulated by estrogen receptor α in breast cancer cells. Endocrinology 2006;147:4831–42.
6. Mungenast F., Thalhammer T. Estrogen biosynthesis and action in ovarian cancer. Front Endocrinol (Lausanne) 2014;5:192.
7. Schuler-Toprak S., Moehle C., Skrzypczak M. et al. Effect of estrogen receptor beta agonists on proliferation and gene expression of ovarian cancer cells. BMC Cancer 2017;17:319.
8. Huzarski T., Byrski T., Gronwald J. et al. Ten-year survival in patients with BRCA1negative and BRCA1-positive breast cancer. J Clin Oncol 2013;31:3191–6.
9. Foulkes W.D., Chappuis P.O., Wong N. et al. Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. Ann Oncol 2000;11:307–13.
10. Moller P., Evans D.G., Reis M.M. et al. Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status. Int J Cancer 2007;121:1017–20.
11. Lee E.H., Park S.K., Park B. et al. Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and metaanalysis. Breast Cancer Res Treat 2010;122:11–25.
12. Cortesi L., Masini C., Cirilli C. et al. Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer. BMC Cancer 2010;10:90.
13. Tryggvadottir L., Olafsdottir E.J., Olafsdottir G.H. et al. Tumour diploidy and survival in breast cancer patients with BRCA2 mutations. Breast Cancer Res Treat 2013;140:375–84.
14. Zhong Q., Peng H.L., Zhao X. et al. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis. Clin Cancer Res 2015;21(1):211–20.
15. Bolton K.L., Chenevix-Trench G., Goh C. et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 2012;307:382–90.
16. Majdak E.J., Debniak J., Milczek T. et al. Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma. Cancer 2005;104:1004–12.
17. Cunningham J.M., Cicek M.S., Larson N.B. et al. Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status. Sci Rep 2014;4:4026.
18. Bolton K.L., Chenevix-Trench G., Goh C. et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 2012;307(4):382–90. DOI: 10.1001/jama.2012.20.
19. Hyman D.M., Zhou Q., Iasonos A. et al. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer 2012;118:3703–9.
20. Yang D., Khan S., Sun Y. et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011;306:1557–65.
21. Vencken P.M., Reitsma W., Kriege M. et al. Outcome of BRCA1-compares with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands. Ann Oncol 2013;24:2036–42.
22. Alsop K., Fereday S., Meldrum C. et al. BRCA mutation frequency and patterns of treatment response in BRCA mutationpositive women with ovarian: a report from the Australia ovarian cancer study group. J Clin Oncol Off J Am Soc Clin Oncol 2012;30:2654–63.
23. Tan D.S., Rothermundt C., Thomas K. et al. “BRCAness” syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol Off J Am Soc Clin Oncol 2008;26:5530–6.
24. McLaughlin J.R., Rosen B., Moody J. et al. Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. J Natl Cancer Inst 2013;105:141–8.
25. Candido-dos-Reis F.J., Song H., Goode E.L. et al. Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer. Clin Cancer Res 2015;21:652–7. 26. Kurta M.L., Edwards R.P., Moysich K.B. et al. Prognosis and conditional disease-free survival among patients with ovarian cancer. J Clin Oncol Off J Am Soc Clin Oncol 2014;32:4102–12.
26. Vencken P.M., Kriege M., Hooning M. et al. The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: implications for counseling. Cancer 2013;119:955–62.
27. Domchek S.M., Jhaveri K., Patil S. et al. Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer. Cancer 2013;119:1344–8.
28. Gangi A., Cass I., Paik D. et al. Breast cancer following ovarian cancer in BRCA mutation carriers. JAMA Surg 2014;149:1306–13.
29. Zhang W., Zhang W., Lin Z. et al. Survival outcomes of patients with primary breast cancer following primary ovarian cancer. Med Sci Monit 2019;25:3869–79.
30. Gangi A., Cass I., Paik D. et al. Breast cancer following ovarian cancer in BRCA mutation carriers. JAMA Surg 2014;149(12):1306–13.
31. Zaaijer L.H., van Doorn H.C., Mourits M.J. et al. Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer 2016;115(10):1174–8.
32. Domchek S.M., Friebel T.M., Singer C.F. et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010;304:967–75.
33. Rebbeck T.R., Kauff N.D., Domchek S.M. Meta-analysis of risk reduction estimates associated with risk-reducing salpingooophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009;8(8):CD012464. DOI: 10.1002/14651858.CD012464.pub2.
34. Heemskerk-Gerritsen B.A.M., Seynaeve C., Van Asperen C.J. et al. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst 2015;107(5):djv033. DOI: 10.1093/jnci/djv033.
35. Heemskerk-Gerritsen B.A.M., Rookus M.A., Aalfs C.M. et al. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. Int J Cancer 2015;136(3):668–77. DOI: 10.1002/ijc.29032.
36. Soenderstrup I.M.H., Laenkholm A.V., Jensen M.B. et al. Clinical and molecular characterization of BRCA-associated breast cancer: Results from the DBCG. Acta Oncol 2018;57:95–101.
37. Schmidt M.K., van den Broek A.J., Tollenaar R.A. et al. Breast cancer survival of BRCA1/BRCA2 mutation carriers in a hospital-based cohort of young women. J Natl Cancer Inst 2017;109:djw329. DOI: 10.1093/jnci/djw329.
38. Van Sprundel T.C., Schmidt M.K., Rookus M.A. et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer 2005;93:287–92.
39. Tung N.M., Boughey J.C., Pierce L.J. et al. Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. J Clin Oncol 2020;38(18):2080–106.
40. Walsh T., King MC. Ten genes for inherited breast cancer. Cancer Cell 2007;11:103–5.
41. National Research Genome Institute (NIH). Learning about the BRCAX study. Available at: http://www.genome. gov/10000532.
42. Eisen A., Lubinski J., Klijn J. et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 pathogenic variant carriers: international case-control study. J Clin Oncol 2005;23:7491–6.
43. Robson M.E., Chappuis P.O., Satagopan J. et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 2004.
44. Kirova Y.M., Stoppa-Lyonnet D., Savignoni A. et al. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer 2005;41:2304–11.
45. Brekelmans C.T., Tilanus-Linthorst M.M., Seynaeve C. et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer 2007;43:867–76.
46. Pierce L.J., Levin A.M., Rebbeck T.R. et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 2006; 24(16):2437–43. DOI: 10.1200/JCO.2005.02.7888.
47. Pierce L.J., Phillips K.A., Griffith K.A. et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat 2010;121(2):389–98. DOI: 10.1007/s10549-010-0894-z.
48. Nilsson M.P., Hartman L., Kristoffersson U. et al. High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer. Breast Cancer Res Treat 2014;147:571–8.
49. Haffty B.G., Harrold E., Khan A.J. et al. Outcome of conservatively managed early onset breast cancer by BRCA1/2 status. Lancet 2002;359(9316):1471–7. DOI: 10.1016/S0140-6736(02)08434-9.
50. Van den Broek A.J., Schmidt M.K., van ’t Veer LJ. et al. Prognostic impact of breast-conserving therapy versus mastectomy of BRCA1/2 mutation carriers compared with noncarriers in a consecutive series of young breast cancer patients. Ann Surg 2019;270:364–72.
51. «Золотой стандарт» диагностики и лечения рака молочной железы 2021. Российское общество онкомаммологов. Версия 2.0.
52. Boyd J., Sonoda Y., Federici M.G. et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000;283(17):2260–5.
53. Du Bois A., Vergote I., Ferron G. et al. Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20. J Clin Oncol 2017;35(Suppl): abstract 5501.
54. Van Driel W.J., Koole S.N., Sikorska K. et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 2018;378(3):230–40.
55. Chiva L.M., Gonzalez-Martin A. A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer. Gynecol Oncol 2015;136(1):130–5. DOI: 10.1016/j.ygyno.2014.11.072.
56. Arun B., Bayraktar S., Liu D.D. et al. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: A single-institution experience. J Clin Oncol 2011;29:3739–46.
57. Silver D.P., Richardson A.L., Eklund A.C. et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 2010;28:1145–53.
58. Byrski T., Huzarski T., Dent R. et al. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2014;147:401–5.
59. Hahnen E., Lederer B., Hauke J. et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: Secondary analysis of the GeparSixto randomized clinical trial. JAMA Oncol 2017;3:1378–85.
60. Loibl S., O’Shaughnessy J., Untch M. et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol 2018;19(4):497–509.
61. Tung N., Arun B., Hacker M.R. et al. Randomized phase II study of neoadjuvant cisplatin versus doxorubicincyclophosphamide in germline BRCA carriers with HER2-negative breast cancer (the INFORM trial). J Clin Oncol 2020;38(14):1539–48.
62. Robson M., Im S.A., Senkus E. et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 2017;377(6):523–33. DOI: 10.1056/NEJMoa1706450. Erratum in: N Engl J Med 2017;377(17):1700.
63. Litton JK., Rugo HS., Ettl J. et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018 Aug 23;379(8):753-763
64. Litton J.K., Scoggins M.E., Hess K.R. et al. Neoadjuvant talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant. J Clin Oncol 2020;38(5):388–94.
65. Dieras V., Han H.S., Kaufman B. et al. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, doubleblind, placebo-controlled, phase 3 trial. Lancet Oncol 2020;21(10):1269–82.
66. Gruber J.J., Afghahi A., Hatton A. et al. Talazoparib beyond BRCA: A phase II trial of talazoparib monotherapy in BRCA1 and BRCA2 wild-type patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous recombination (HR) pathway genes. J Clinl Oncol 2019;37:3006.
67. Moore K., Colombo N., Scambia G. et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018;379(26):2495–505.
68. Ledermann J., Harter P., Gourley C. et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366(15):1382–92.
69. Pujade-Lauraine E., Ledermann J.A., Selle F. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2017;18(9):1274–84.
70. Mirza M.R., Monk B.J., Herrstedt J. et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 2016;375(22): 2154–64.
71. Del Campo J.M., Matulonis U.A., Malander S. et al. Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA trial. J Clin Oncol 2019;37(32):2968–73.
72. Coleman R.L., Oza A.M., Lorusso D. et al. ARIEL3 investigators. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebocontrolled, phase 3 trial. Lancet 2017;390(10106):1949–61.
73. Vos J.R., Fakkert I.E., de Hullu J.A. et al. OPA Working Group. Universal tumor DNA BRCA1/2 testing of ovarian cancer: Prescreening PARPi treatment and genetic predisposition. J Natl Cancer Inst 2020;112(2):161–9.
74. Hodgson D.R., Dougherty B.A., Lai Z. et al. Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. Br J Cancer 2018;119:1401–9.
Рецензия
Для цитирования:
Семиглазов В.В., Протасова А.Э., Каликеев Г.К. Особенности клинического течения и лечения наследственных форм рака молочной железы и рака яичников. Опухоли женской репродуктивной системы. 2020;16(4):54-65. https://doi.org/10.17650/1994-4098-2020-16-4-54-65
For citation:
Semiglazov V.V., Protasova A.Е., Kalikeev G.K. Hereditary breast cancer and ovarian cancer: clinical course and treatment. Tumors of female reproductive system. 2020;16(4):54-65. (In Russ.) https://doi.org/10.17650/1994-4098-2020-16-4-54-65
Просмотров:
771
Послать статью по эл. почте 